SCYNEXIS, Inc. (SCYX)
Develops medicines to treat drug-resistant fungal infections.
$3.63+0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-33.4%
The outlook
SCYX trades at $3.63, sitting near its 52-week lows with price below both its 50- and 200-day moving averages. Analyst coverage shows a wide gap, with the average price target implying substantial upside, though the overall sentiment leans bearish. The stock remains in a weak technical position relative to its recent range.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +824% vs current price
Analyst price target
~12-month · 3 analysts$33.55average target+824.2% vs now
Now $3.63
Low $24.00High $44.64
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$36.0M
52-wk high
$10.48
52-wk low
$3.53
50-day avg
$4.59
200-day avg
$5.78
Trailing P/E
—